Computational drug repurposing strategy predicted peptide-based drugs that can potentially inhibit the interaction of SARS-CoV-2 spike protein with its target (humanACE2)

被引:25
|
作者
Egieyeh, Samuel [1 ]
Egieyeh, Elizabeth [2 ]
Malan, Sarel [3 ]
Christofells, Alan [4 ]
Fielding, Burtram [5 ]
机构
[1] Univ Western Cape, Sch Pharm, Pharmacol & Clin Pharm Unit, Computat Pharmacol & Cheminformat Res Grp, Cape Town, South Africa
[2] Univ Western Cape, Sch Pharm, Pharmacol & Clin Pharm Unit, Cape Town, South Africa
[3] Univ Western Cape, Sch Pharm, Pharmaceut Chem Unit, Cape Town, South Africa
[4] Univ Western Cape, South African Natl Bioinformat Inst, South African Med Res Council, Bioinformat Unit, Cape Town, South Africa
[5] Univ Western Cape, Dept Med Biosci, Mol Biol & Virol Res Lab, Cape Town, South Africa
来源
PLOS ONE | 2021年 / 16卷 / 01期
关键词
ACE2;
D O I
10.1371/journal.pone.0245258
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Drug repurposing for COVID-19 has several potential benefits including shorter development time, reduced costs and regulatory support for faster time to market for treatment that can alleviate the current pandemic. The current study used molecular docking, molecular dynamics and protein-protein interaction simulations to predict drugs from the Drug Bank that can bind to the SARS-CoV-2 spike protein interacting surface on the human angiotensin-converting enzyme 2 (hACE2) receptor. The study predicted a number of peptide-based drugs, including Sar9 Met (O2)11-Substance P and BV2, that might bind sufficiently to the hACE2 receptor to modulate the protein-protein interaction required for infection by the SARS-CoV-2 virus. Such drugs could be validated in vitro or in vivo as potential inhibitors of the interaction of SARS-CoV-2 spike protein with the human angiotensin-converting enzyme 2 (hACE2) in the airway. Exploration of the proposed and current pharmacological indications of the peptide drugs predicted as potential inhibitors of the interaction between the spike protein and hACE2 receptor revealed that some of the predicted peptide drugs have been investigated for the treatment of acute respiratory distress syndrome (ARDS), viral infection, inflammation and angioedema, and to stimulate the immune system, and potentiate antiviral agents against influenza virus. Furthermore, these predicted drug hits may be used as a basis to design new peptide or peptidomimetic drugs with better affinity and specificity for the hACE2 receptor that may prevent interaction between SARS-CoV-2 spike protein and hACE2 that is prerequisite to the infection by the SARS-CoV-2 virus.
引用
收藏
页数:14
相关论文
共 50 条
  • [31] Computational drug repurposing study of the RNA binding domain of SARS-CoV-2 nucleocapsid protein with antiviral agents
    Tatar, Gizem
    Ozyurt, Ezgi
    Turhan, Kemal
    BIOTECHNOLOGY PROGRESS, 2021, 37 (02)
  • [32] Peptide-Based Inhibitors of Protein-Protein Interactions (PPIs): A Case Study on the Interaction Between SARS-CoV-2 Spike Protein and Human Angiotensin-Converting Enzyme 2 (hACE2)
    Rakhmetullina, Aizhan
    Zielenkiewicz, Piotr
    Odolczyk, Norbert
    BIOMEDICINES, 2024, 12 (10)
  • [33] A Computational-Based Drug Repurposing Method Targeting SARS-CoV-2 and its Neurological Manifestations Genes and Signaling Pathways
    Sepehrinezhad, Ali
    Rezaeitalab, Fariborz
    Shahbazi, Ali
    Sahab-Negah, Sajad
    BIOINFORMATICS AND BIOLOGY INSIGHTS, 2021, 15
  • [34] Distinct Conformations of SARS-CoV-2 Omicron Spike Protein and Its Interaction with ACE2 and Antibody
    Lee, Myeongsang
    Major, Marian
    Hong, Huixiao
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2023, 24 (04)
  • [35] A Dynamic and Effective Peptide-Based Strategy for Promptly Addressing Emerging SARS-CoV-2 Variants of Concern
    Murdocca, Michela
    Romeo, Isabella
    Citro, Gennaro
    Latini, Andrea
    Centofanti, Federica
    Bugatti, Antonella
    Caccuri, Francesca
    Caruso, Arnaldo
    Ortuso, Francesco
    Alcaro, Stefano
    Sangiuolo, Federica
    Novelli, Giuseppe
    PHARMACEUTICALS, 2024, 17 (07)
  • [36] Dalbavancin binds ACE2 to block its interaction with SARS-CoV-2 spike protein and is effective in inhibiting SARS-CoV-2 infection in animal models
    Wang, Gan
    Yang, Meng-Li
    Duan, Zi-Lei
    Liu, Feng-Liang
    Jin, Lin
    Long, Cheng-Bo
    Zhang, Min
    Tang, Xiao-Peng
    Xu, Ling
    Li, Ying-Chang
    Kamau, Peter Muiruri
    Yang, Lian
    Liu, Hong-Qi
    Xu, Jing-Wen
    Chen, Jie-Kai
    Zheng, Yong-Tang
    Peng, Xiao-Zhong
    Lai, Ren
    CELL RESEARCH, 2021, 31 (01) : 17 - 24
  • [37] Dalbavancin binds ACE2 to block its interaction with SARS-CoV-2 spike protein and is effective in inhibiting SARS-CoV-2 infection in animal models
    Gan Wang
    Meng-Li Yang
    Zi-Lei Duan
    Feng-Liang Liu
    Lin Jin
    Cheng-Bo Long
    Min Zhang
    Xiao-Peng Tang
    Ling Xu
    Ying-Chang Li
    Peter Muiruri Kamau
    Lian Yang
    Hong-Qi Liu
    Jing-Wen Xu
    Jie-Kai Chen
    Yong-Tang Zheng
    Xiao-Zhong Peng
    Ren Lai
    Cell Research, 2021, 31 : 17 - 24
  • [38] Potential SARS-CoV-2 nonstructural proteins inhibitors: drugs repurposing with drug-target networks and deep learning
    Azmoodeh, Shayan K.
    Tsigelny, Igor F.
    Kouznetsova, Valentina L.
    FRONTIERS IN BIOSCIENCE-LANDMARK, 2022, 27 (04):
  • [39] Interaction analyses of SARS-CoV-2 spike protein based on fragment molecular orbital calculations
    Akisawa, Kazuki
    Hatada, Ryo
    Okuwaki, Koji
    Mochizuki, Yuji
    Fukuzawa, Kaori
    Komeiji, Yuto
    Tanaka, Shigenori
    RSC ADVANCES, 2021, 11 (06) : 3272 - 3279
  • [40] Repurposing of the approved small molecule drugs in order to inhibit SARS-CoV-2 S protein and human ACE2 interaction through virtual screening approaches
    Kalhor, Hourieh
    Sadeghi, Solmaz
    Abolhasani, Hoda
    Kalhor, Reyhaneh
    Rahimi, Hamzeh
    JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS, 2022, 40 (03): : 1299 - 1315